Literature DB >> 33020146

Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells.

Patrick Innamarato1,2, Sarah Asby1, Jennifer Morse1, Amy Mackay1, MacLean Hall1,2, Scott Kidd1, Luz Nagle1, Amod A Sarnaik1,3, Shari Pilon-Thomas4.   

Abstract

The activation of 41BB costimulatory signals by agonistic Abs enhances the expansion and function of tumor-infiltrating lymphocytes (TILs) for treating cancer patients with adoptive cell therapy. However, the impact of 41BB agonism is not limited to enhancing the activity of T cells, and the mechanism by which additional activation of this costimulatory axis in tumor-associated myeloid cells is poorly understood. In this study, we describe that the intratumoral administration of 41BB agonistic Abs led to increases in CD8 T cell infiltration followed by tumor regression in murine models. We found that granulocytes and monocytes rapidly replaced macrophages and dendritic cells in tumors following administration of anti-41BB Abs. Overall, myeloid cells from anti-41BB-treated tumors had an improved capacity to stimulate T cells in comparison with control-treated tumors. In human coculture systems, we demonstrated that the agonism of the 41BB-41BBL axis enhanced costimulatory signals and effector functions among APC and autologous TILs. Overall, these findings suggest that the effect of 41BB agonistic Abs are supported by additional costimulatory signals from tumor-associated myeloid cells,v leading to enhanced TIL expansion and function.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33020146      PMCID: PMC7741883          DOI: 10.4049/jimmunol.2000759

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  CD137 ligand signaling induces human monocyte to dendritic cell differentiation.

Authors:  Shaqireen Kwajah M M; Herbert Schwarz
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 2.  CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction.

Authors:  Zhe Shao; Herbert Schwarz
Journal:  J Leukoc Biol       Date:  2010-07-19       Impact factor: 4.962

3.  CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling.

Authors:  J Langstein; J Michel; J Fritsche; M Kreutz; R Andreesen; H Schwarz
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

4.  Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Authors:  Christina Claus; Claudia Ferrara; Wei Xu; Johannes Sam; Sabine Lang; Franziska Uhlenbrock; Rosmarie Albrecht; Sylvia Herter; Ramona Schlenker; Tamara Hüsser; Sarah Diggelmann; John Challier; Ekkehard Mössner; Ralf J Hosse; Thomas Hofer; Peter Brünker; Catherine Joseph; Jörg Benz; Philippe Ringler; Henning Stahlberg; Matthias Lauer; Mario Perro; Stanford Chen; Christine Küttel; Preethi L Bhavani Mohan; Valeria Nicolini; Martina Carola Birk; Amandine Ongaro; Christophe Prince; Reto Gianotti; Gregory Dugan; Christopher T Whitlow; Kiran Kumar Solingapuram Sai; David L Caudell; Armando G Burgos-Rodriguez; J Mark Cline; Michael Hettich; Maurizio Ceppi; Anna Maria Giusti; Flavio Crameri; Wouter Driessen; Peter N Morcos; Anne Freimoser-Grundschober; Victor Levitsky; Maria Amann; Sandra Grau-Richards; Thomas von Hirschheydt; Stella Tournaviti; Michael Mølhøj; Tanja Fauti; Viola Heinzelmann-Schwarz; Volker Teichgräber; Sara Colombetti; Marina Bacac; Alfred Zippelius; Christian Klein; Pablo Umaña
Journal:  Sci Transl Med       Date:  2019-06-12       Impact factor: 17.956

5.  Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.

Authors:  Shari Pilon-Thomas; Lisa Kuhn; Sabine Ellwanger; William Janssen; Erica Royster; Suroosh Marzban; Ragini Kudchadkar; Jonathan Zager; Geoffrey Gibney; Vernon K Sondak; Jeffrey Weber; James J Mulé; Amod A Sarnaik
Journal:  J Immunother       Date:  2012-10       Impact factor: 4.456

6.  CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses.

Authors:  Zulkarnain Harfuddin; Shaqireen Kwajah; Adrian Chong Nyi Sim; Paul Anthony Macary; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2013-11-11       Impact factor: 8.110

7.  Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.

Authors:  Jessica Ann Hernandez-Chacon; Yufeng Li; Richard C Wu; Chantale Bernatchez; Yijun Wang; Jeffrey S Weber; Patrick Hwu; Laszlo G Radvanyi
Journal:  J Immunother       Date:  2011-04       Impact factor: 4.456

8.  Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Authors:  Jessica Ann Chacon; Amod A Sarnaik; Jie Qing Chen; Caitlin Creasy; Charuta Kale; John Robinson; Jeffrey Weber; Patrick Hwu; Shari Pilon-Thomas; Laszlo Radvanyi
Journal:  Clin Cancer Res       Date:  2014-12-03       Impact factor: 12.531

9.  Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.

Authors:  S Michael Chin; Christopher R Kimberlin; Zygy Roe-Zurz; Pamela Zhang; Allison Xu; Sindy Liao-Chan; Debasish Sen; Andrew R Nager; Nicole Schirle Oakdale; Colleen Brown; Feng Wang; Yuting Yang; Kevin Lindquist; Yik Andy Yeung; Shahram Salek-Ardakani; Javier Chaparro-Riggers
Journal:  Nat Commun       Date:  2018-11-08       Impact factor: 14.919

10.  A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.

Authors:  Marta Compte; Seandean Lykke Harwood; Ines G Muñoz; Rocio Navarro; Manuela Zonca; Gema Perez-Chacon; Ainhoa Erce-Llamazares; Nekane Merino; Antonio Tapia-Galisteo; Angel M Cuesta; Kasper Mikkelsen; Eduardo Caleiras; Natalia Nuñez-Prado; M Angela Aznar; Simon Lykkemark; Jorge Martínez-Torrecuadrada; Ignacio Melero; Francisco J Blanco; Jorge Bernardino de la Serna; Juan M Zapata; Laura Sanz; Luis Alvarez-Vallina
Journal:  Nat Commun       Date:  2018-11-15       Impact factor: 14.919

View more
  2 in total

1.  Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine.

Authors:  Soledad Palameta; Andrea J Manrique-Rincón; Jessica M Toscaro; Isadora F Semionatto; Matheus C Fonseca; Rhubia S M Rosa; Luciana P Ruas; Paulo S L Oliveira; Marcio C Bajgelman
Journal:  Mol Ther Oncolytics       Date:  2022-02-17       Impact factor: 7.200

2.  Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors.

Authors:  Patrick Innamarato; Jennifer Morse; Amy Mackay; Sarah Asby; Matthew Beatty; Jamie Blauvelt; Scott Kidd; John E Mullinax; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  BMC Cancer       Date:  2021-06-30       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.